Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
ID: 357355Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357355
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for studying Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, providing a total funding ceiling of $1,338,000 over a potential seven-year period, contingent upon the successful completion of defined milestones. The project is critical for advancing research in hemophilia treatment and will involve a collaborative effort with a companion award for a Biospecimen and Data Resource Center. Interested applicants can reach out to Iman K. Martin, PhD, MPH, MS at iman.martin@nih.gov or call 301-435-0065 for further details, with the estimated synopsis post date having been set for March 2, 2020.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in non-malignant hematology. This initiative invites investigator-initiated research project grant applications (R01) that focus on basic and early translational hematology research, with a particular emphasis on fostering diverse perspectives within research teams through a required Plan for Enhancing Diverse Perspectives (PEDP). Approximately $2.5 million is available for 5-8 awards, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in nonmalignant hematology. This program invites investigator-initiated R01 grant applications that focus on emerging topics such as blood cell development, the effects of aging on hematopoiesis, and metabolic influences on blood cell formation, with the goal of advancing the field of hematology. The total funding available for this initiative is approximately $2.15 million for fiscal year 2022, with an estimated 2-9 grants to be awarded, and applications must be submitted through Grants.gov by January 7, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the establishment of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 cooperative agreement mechanism. This initiative aims to facilitate trials focused on efficacy, comparative effectiveness, and implementation research, particularly those that address health disparities and promote community engagement. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofit entities, and tribal governments, with applications required to detail project management, participant recruitment strategies, and a Plan for Enhancing Diverse Perspectives (PEDP). The application period opens on January 11, 2025, with a submission deadline of September 11, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 activity codes. This initiative aims to foster innovative trial designs relevant to the National Heart, Lung, and Blood Institute's (NHLBI) research mission, requiring comprehensive project plans that address participant recruitment, milestone achievements, and strategies for enhancing community engagement and diversity. The funding mechanism is bi-phasic and necessitates simultaneous applications for both a CCC and a collaborating Data Coordinating Center (DCC), emphasizing strong project management and a commitment to minimizing health disparities. Interested applicants must submit their proposals by September 11, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html.
    Hereditary Hemorrhagic Telangiectasia (HHT) Center
    Active
    Health Resources and Services Administration
    The Health Resources and Services Administration (HRSA) is forecasting a grant opportunity titled "Hereditary Hemorrhagic Telangiectasia (HHT) Center," aimed at reducing morbidity and mortality associated with HHT. The program's objectives include expanding access to care for HHT patients and developing a de-identified patient data registry to enhance understanding of this rare disease and its treatment outcomes. This cooperative agreement is crucial for improving health outcomes for affected individuals and is open to various domestic public or private entities, including faith-based organizations. The estimated total program funding is $2,000,000, with one award expected, and interested applicants should note that the synopsis is anticipated to be posted on January 10, 2025, with a closing date of April 11, 2025. For further inquiries, applicants can contact Nordia Williams at (240) 475-3310 or via email at Nwilliams1@hrsa.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.